Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Kiromic BioPharma, Inc. (KRBP)

4.11   0.18 (4.58%) 03-24 15:59
Open: 3.95 Pre. Close: 3.93
High: 4.1599 Low: 3.95
Volume: 10,390 Market Cap: 3(M)

Technical analysis

as of: 2023-03-24 4:27:33 PM
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Target: Six months: 7.63     One year: 8.92
Support: Support1: 2.58    Support2: 0.13
Resistance: Resistance1: 6.53    Resistance2: 7.63
Pivot: 2.91
Moving Average: MA(5): 4.14     MA(20): 2.22
MA(100): 0.62     MA(250): 0.51
MACD: MACD(12,26): 1     Signal(9): 0.9
Stochastic oscillator: %K(14,3): 61.7     %D(3): 62.6
RSI: RSI(14): 73.6
52-week: High: 6.53  Low: 0.13
Average Vol(K): 3-Month: 2,112 (K)  10-Days: 174 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ KRBP ] has closed below upper band by 34.7%. Bollinger Bands are 874.2% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 9 days. This is a sign that the current trend might continue.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 4.17 - 4.19 4.19 - 4.21
Low: 3.89 - 3.92 3.92 - 3.95
Close: 4.07 - 4.11 4.11 - 4.15

Company Description

Kiromic BioPharma, Inc., an artificial intelligence driven allogeneic cell therapy company, engages in developing the multi-indication allogeneic T cell therapies that exploits the natural potency of the Gamma Delta T cell to target solid tumors. The company develops ALEXIS-ISO-1, an allogenic gamma delta CAR-T cell therapy product candidate targeting Isomesothelin; and ALEXIS-PRO-1, an allogeneic gamma delta chimeric T cell therapy product candidate targeting PD-L1. It has license agreements with CGA 369 Intellectual Holdings, Inc. and Longwood University, as well as a research and development collaboration agreement with Molipharma, S.R.L. The company also has strategic alliance agreement with Leon Office (H.K.) Ltd. The company was formerly known as Kiromic, Inc. and changed its name to Kiromic BioPharma, Inc. in December 2019. Kiromic BioPharma, Inc. was founded in 2006 and is headquartered in Houston, Texas.

Headline News

Fri, 17 Mar 2023
Will Kiromic Biopharma Inc (KRBP) Stay at the Bottom of the Healthcare Sector? - InvestorsObserver

Wed, 15 Mar 2023
Healthcare Stocks on the Move Wednesday: THMO, MLEC, ELEV, JNCE, EUDA, SY, KRBP, ONCS - InvestorsObserver

Thu, 09 Mar 2023
What is the Market's View on Kiromic Biopharma Inc (KRBP) Stock's Price and Volume Trends Thursday? - InvestorsObserver

Thu, 09 Mar 2023
Why Cassava Sciences Shares Are Trading Higher By 12%; Here ... - UK

Thu, 09 Mar 2023
Nano Caps With Big Breakout Potential (EPAZ, HNRC, KRBP, NLTX) -

Tue, 28 Feb 2023
Is Kiromic Biopharma Inc (KRBP) Stock a Good Value? - InvestorsObserver

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Neutral
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 21 (M)
Shares Float 15 (M)
% Held by Insiders 5.8 (%)
% Held by Institutions 15.6 (%)
Shares Short 332 (K)
Shares Short P.Month 218 (K)

Stock Financials

EPS -2.25
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0.66
Profit Margin (%) 0
Operating Margin (%) 0
Return on Assets (ttm) -82.9
Return on Equity (ttm) -202.7
Qtrly Rev. Growth 0
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -1.62
Qtrly Earnings Growth 0
Operating Cash Flow -29 (M)
Levered Free Cash Flow -17 (M)

Stock Valuations

PE Ratio -1.84
PEG Ratio 0
Price to Book value 6.22
Price to Sales 0
Price to Cash Flow -2.93

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.